What are the differences in potency among the various insulin formulations (rapid‑acting, short‑acting, intermediate‑acting, long‑acting, ultra‑long‑acting) and concentrations (U‑100, U‑200, U‑300, U‑500)?

Insulin Strength Differences: Concentration and Potency

The primary difference in insulin "strength" refers to concentration (units per mL), not biological potency—all insulin formulations have equivalent glucose-lowering effect per unit, but concentrated insulins deliver more units in smaller volumes.

Standard vs. Concentrated Insulin Formulations

U-100 (Standard Concentration)

• U-100 insulin contains 100 units per mL and represents the standard concentration for most insulin preparations globally. 1
• This concentration is used for the vast majority of basal insulins (glargine, detemir, degludec), rapid-acting analogs (lispro, aspart, glulisine), and regular insulin. 1
• U-100 formulations are compatible with standard insulin syringes and most insulin pens. 1

U-200 (Double Concentration)

• Insulin lispro U-200 and insulin degludec U-200 contain 200 units per mL—exactly twice the concentration of U-100. 23
• These formulations are bioequivalent to their U-100 counterparts, meaning the pharmacokinetic and pharmacodynamic profiles are identical per unit of insulin. 4
• No dose adjustment is required when switching between U-100 and U-200 formulations of the same insulin type—50 units of lispro U-200 has the same effect as 50 units of lispro U-100. 35
• The primary advantage is reduced injection volume: 50 units of U-200 requires only 0.25 mL versus 0.5 mL for U-100, which may improve absorption and reduce injection site reactions. 63
• U-200 insulins are delivered via dedicated pens only—they cannot be drawn into standard syringes due to dosing error risk. 5

U-300 (Triple Concentration)

• Insulin glargine U-300 (Toujeo) contains 300 units per mL—three times the concentration of U-100 glargine (Lantus). 23
• Unlike U-200 formulations, glargine U-300 is not bioequivalent to glargine U-100 due to altered pharmacokinetic properties from the smaller subcutaneous depot. 35
• The higher concentration results in a more prolonged duration of action (beyond 24 hours) and a flatter pharmacodynamic profile compared to U-100 glargine. 3
• When switching from glargine U-100 to U-300, the American Diabetes Association recommends using the same number of units initially, then titrating based on glucose response—some patients may require 10-18% more total daily dose with U-300 to achieve equivalent glycemic control. 73
• U-300 is available only in prefilled pens with specific dose increments. 5

U-500 (Five-Fold Concentration)

• Human regular insulin U-500 (Humulin R U-500) contains 500 units per mL—five times more concentrated than U-100. 26
• This formulation has unique pharmacodynamic properties: it functions as both a basal and prandial insulin due to its prolonged absorption, with onset at 30-45 minutes, peak at 4-8 hours, and duration of 13-24 hours. 63
• U-500 is specifically indicated for patients with severe insulin resistance requiring total daily doses exceeding 200 units, where U-100 formulations would necessitate impractically large injection volumes. 63
• Critical safety consideration: U-500 requires a dedicated U-500 pen or U-500-specific syringes—using standard U-100 syringes results in a 5-fold overdose and life-threatening hypoglycemia. 65
• The larger subcutaneous depot created by U-500's concentration leads to slower, more prolonged absorption compared to U-100 regular insulin, fundamentally altering its clinical use. 6

Key Clinical Distinctions

Bioequivalence vs. Non-Bioequivalence

• Bioequivalent concentrated insulins (lispro U-200, degludec U-200): Identical pharmacokinetics per unit; no dose conversion needed; switch unit-for-unit. 34
• Non-bioequivalent concentrated insulins (glargine U-300, regular U-500): Altered pharmacokinetics require dose adjustment and careful titration when switching. 35

Absorption Characteristics

• Higher concentration insulins create smaller subcutaneous depots for the same number of units, which can improve absorption consistency and reduce variability. 63
• The reduced injection volume with concentrated insulins may decrease injection site pain and lipohypertrophy risk. 13

Device Compatibility

• All concentrated insulins (U-200, U-300, U-500) are dispensed in dedicated delivery devices to prevent dosing errors. 5
• Standard U-100 syringes must never be used with concentrated insulins due to catastrophic dosing error risk. 65

Practical Implications

Patient Selection for Concentrated Insulins

• Consider U-200 formulations when total daily insulin exceeds 60-80 units to reduce injection volume and potentially improve adherence. 38
• Reserve U-500 for patients requiring ≥200 units daily with documented severe insulin resistance. 63
• U-300 glargine may benefit patients experiencing nocturnal hypoglycemia on U-100 glargine due to its flatter profile. 3

Switching Between Concentrations

• When transitioning from U-100 to bioequivalent U-200 formulations, prescribe the exact same number of units and educate patients that the pen will show the same dose despite smaller volume. 35
• For glargine U-100 to U-300 conversion, start with the same unit dose but anticipate potential need for 10-18% dose increase during titration. 73
• Never attempt to convert U-500 doses using U-100 syringes—this is a common fatal error. 65

Common Pitfalls

• Assuming concentrated insulins are "stronger" per unit—they are not; 10 units of any insulin formulation has equivalent glucose-lowering potency. 35
• Using standard syringes with concentrated insulins, resulting in massive overdose. 65
• Failing to educate patients that pen dose windows show units, not volume—50 units of U-200 looks like less insulin in the cartridge but delivers the same biological effect. 5
• Not recognizing that U-500's prolonged action profile requires twice-daily dosing (typically before breakfast and dinner) rather than once-daily administration. 6